Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Somministrazione di liquidi nella chetoacidosi (BEVANDA) (DRINK)

5 novembre 2026 aggiornato da: Centre Hospitalier Universitaire de Nice

Confronto tra soluzione salina e lattato di Ringer in pazienti con chetoacidosi diabetica grave (DRINK): uno studio randomizzato e controllato in doppio cieco

Management of severe diabetic ketoacidosis is based on insulin therapy, correction of metabolic disorders and fluid resuscitation. Current recommendations recommend the first-line use of isotonic saline, whose composition is unbalanced, rich in chloride and sodium compared with plasma. Administration of large volumes of isotonic saline is associated with a risk of hyperchloremic metabolic acidosis and acute renal failure. Balanced solutions (e.g. Ringer Lactate) are solutions with a more balanced electrolyte composition close to that of plasma. They could therefore enable diabetic ketoacidosis to be resolved more quickly than isotonic saline, due to a lower risk of hyperchloremic acidosis. Preliminary data suggest a potential benefit of balanced solutions for fluid resuscitation of patients with severe diabetic ketoacidosis in terms of resolution of diabetic ketoacidosis, but no randomized controlled double-blind study to date has compared balanced solution vs. isotonic saline in this context.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

300

Fase

  • Fase 4

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Nice, Francia
        • Reclutamento
        • CHU NICE
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Admission to emergency department or direct admission to ICU
  • Diagnosis of severe diabetic ketoacidosis requiring all the following criteria:
  • Blood or capillary glucose > 11 mmol/L
  • Ketonemia or ketonuria > 0
  • Venous or arterial pH < 7.30 or venous or arterial bicarbonate < 15 mmol/L
  • Volume of fluid administered before inclusion <1L

Exclusion Criteria:

  • Patients <18 years
  • Pregnant women
  • Patients under protection
  • Patients with a decision to withdraw life-sustaining therapy
  • Contraindication to isotonic saline or Ringer Lactate
  • Non-affiliation to social security

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Soluzione salina isotonica

Isotonic saline only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines:

  • During the first hour of treatment:

    • In the event of systolic arterial hypotension (SAP<90mmHg): administration of 500 mL over 15 minutes, renewable once, then administration of 1L over 1 hour.
    • In the absence of systolic arterial hypotension (SAP>90mmHg): administration of 1L over 1 hour.
  • Between 60 minutes and 8 hours of treatment :

    • 1L over 2 hours, repeated once, then 1L over 4 hours
    • Adjust fluid resuscitation according to clinical tolerance
  • After the first 8 hours:

    • 1L over 4h then 1L over 6h
    • Clinical re-evaluation according to standard of care in participating centers
Sperimentale: Ringer lattato

Ringer Lactate only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines:

  • During the first hour of treatment:

    • In the event of systolic arterial hypotension (SAP<90mmHg): administration of 500 mL over 15 minutes, renewable once, then administration of 1L over 1 hour.
    • In the absence of systolic arterial hypotension (SAP>90mmHg): administration of 1L over 1 hour.
  • Between 60 minutes and 8 hours of treatment :

    • 1L over 2 hours, repeated once, then 1L over 4 hours
    • Adjust fluid resuscitation according to clinical tolerance
  • After the first 8 hours:

    • 1L over 4h then 1L over 6h
    • Clinical re-evaluation according to standard of care in participating centers

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Resolution of diabetic ketoacidosis
Lasso di tempo: at 24 hours

Compare fluid resuscitaiton with Ringer Lactate to isotonic saline on the resolution of diabetic ketoacidosis at 24 hours from admission to Intensive Care Unit (ICU) in patients with severe diabetic ketoacidosis.

Resolution of ketoacidosis allowing discharge from ICU, defined as the proportion of patients with the following three criteria at 24 hours from ICU admission :

  1. capillary or blood glucose < 11 mmol/L
  2. ketonemia < 0.6 mmol/l
  3. venous or arterial pH ≥ 7,30 or venous or arterial bicarbonate ≥ 18 mmol/L
at 24 hours

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Speed of resolution of metabolic disorders
Lasso di tempo: at 48 hours

Compare fluid resuscitation with Ringer Lactate and isotonic saline solution on the speed of resolution of metabolic disorders in patients admitted to ICU for severe diabetic ketoacidosis.

Proportion of patients and number of hours ("Resolution free hours") within 48 hours of ICU admission with the following three criteria:

  1. capillary or blood glucose < 11 mmol/L
  2. ketonemia < 0.6 mmol/l
  3. venous or arterial pH ≥ 7,30 or venous or arterial bicarbonate ≥ 18 mmol/L
at 48 hours
Time of resolution of metabolic disorders
Lasso di tempo: at 48 hours

Compare fluid resuscitation with Ringer Lactate and isotonic saline solution on the speed of resolution of metabolic disorders in patients admitted to ICU for severe diabetic ketoacidosis.

Time (in hours) from ICU admission to obtain one of the following three criteria:

  1. capillary or blood glucose < 11 mmol/L
  2. ketonemia < 0.6 mmol/l
  3. venous or arterial pH ≥ 7,30 or venous or arterial bicarbonate ≥ 18 mmol/L
at 48 hours
Assess the metabolic tolerance of Ringer Lactate compared to isotonic saline solution
Lasso di tempo: through the end of study average 24 months

Assess the metabolic tolerance of Ringer Lactate compared to isotonic saline solution in patients admitted to ICU for severe diabetic ketoacidosis.

Occurrence of serious metabolic disorders during ICU stay, defined as :

  1. Kalemia < 3 mmol/L
  2. Natremia > 145 mmol/L
  3. Chloremia > 110 mmol/L
  4. Phosphoremia < 0.70 mmol/L
  5. Blood glucose < 3.8 mmol/L (i.e. 0.80 g/L)
  6. Persistent ketonemia/ketonuria 24 hours after ICU admission 2. Nature and volume (in liters) of fluid administered before inclusion and during the study period in each group 3. Protocol compliance (expressed as % of volume administered in each group)
through the end of study average 24 months
Assess the impact of Ringer lactate compared with isotonic saline on renal, neurological and cardiac complications
Lasso di tempo: at 28 days

To assess the impact of Ringer lactate compared with isotonic saline on renal, neurological and cardiac complications during ICU stay and outcomes of patients admitted to ICU for severe diabetic ketoacidosis.

Occurrence of adverse events during ICU stay, defined as :

  1. Neurological disorders (Glasgow score)
  2. Acute renal failure (KDIGO classification)
  3. Cardiac disorders (supraventricular and ventricular rhythm disorders, acute coronary syndrome) 2. ICU and hospital length of stay 3. ICU mortality and Day-28 mortality
at 28 days
Assess the impact of Ringer lactate compared with isotonic saline on cardiac complications
Lasso di tempo: at 28 days

To assess the impact of Ringer lactate compared with isotonic saline on cardiac complications during ICU stay and outcomes of patients admitted to ICU for severe diabetic ketoacidosis.

Occurrence of adverse events during ICU stay, defined as :

  • Cardiac disorders (supraventricular and ventricular rhythm disorders, acute coronary syndrome)
  • ICU and hospital length of stay
  • ICU mortality and Day-28 mortality
at 28 days
Assess the impact of Ringer lactate compared with isotonic saline on renal complications
Lasso di tempo: at 28 days

To assess the impact of Ringer lactate compared with isotonic saline on renal, complications during ICU stay and outcomes of patients admitted to ICU for severe diabetic ketoacidosis.

Measure acute renal failure with KDIGO classification.

The Kidney Disease: Improving Global Outcomes (KDIGO) classification system stratifies acute kidney injury (AKI) into levels of severity, determined by changes in serum creatinine (SCr) / estimated creatinine clearance (eCCl), as well as changes in urine output. The strata of severity of AKI can be reached by meeting the criteria for changes in SCr / eCCl or changes in urine output. There are three levels of severity, with level 1 being the least severe and level 3 the most severe.

No cut-off for the study

at 28 days
Assess the impact of Ringer lactate compared with isotonic saline on neurological complications
Lasso di tempo: at 28 days

To assess the impact of Ringer lactate compared with isotonic saline on neurological complications during ICU stay and outcomes of patients admitted to ICU for severe diabetic ketoacidosis.

Measure Neurological disorders with Glasgow score. The Glasgow Coma Scale (GCS) is used to objectively describe the extent of impaired consciousness in all types of patients. The scale rates patients on three aspects of reactivity: eye opening, motor responses and verbal responses. It ranges from 3 (coma) to 15 (no disturbance of consciousness). No cut-off for the study.

at 28 days

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

26 novembre 2025

Completamento primario (Stimato)

1 dicembre 2027

Completamento dello studio (Stimato)

1 luglio 2028

Date di iscrizione allo studio

Primo inviato

8 luglio 2024

Primo inviato che soddisfa i criteri di controllo qualità

2 agosto 2024

Primo Inserito (Effettivo)

7 agosto 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

5 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 22-API-03

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .